For the Treatment of Chronic Tophaceous Gout, a Drug That Resolves Tophi in Less Than One Year Would Become the Patient Share Leader in the U.S. and Europe
Advertisement
Savient Pharmaceuticals' Krystexxa Will Become Decision Resources' Clinical Gold Standard in 2013